ArticleOsteoarthritis and cartilage open2026
Clonal articular cartilage progenitors outperform mesenchymal stromal cells in mitigating post-traumatic osteoarthritis.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the functional, pathological, and immunomodulatory properties of articular chondroprogenitors (ACPs) with those of bone-marrow-derived mesenchymal stromal cells (MSCs) in preventing the progression of post-traumatic osteoarthritis (PTOA) after destabilization of the medial meniscus (DMM) injury in a mouse model. Method: ACP and MSC were isolated from three horses and assessed for their immunomodulatory capacity in vitro. Aliquots of selected ACP clones and MSCs were injected intra-articularly into male mice 1-week post destabilization of the medial meniscus (DMM). The functional mobility of the mice before the injury and at weeks 2, 4, and 8 post-injury was assessed by two methods: ANY-maze™ voluntary mobility monitoring and DigiGait™ compulsory gait analysis. Upon euthanasia, joints were collected for histological scoring. Results: In vitro assessments demonstrated that ACPs and MSCs had anti-inflammatory properties: both treatments produced lower levels of pro-inflammatory cytokines, while only the ACPs produced more anti-inflammatory cytokines than controls. In vivo, both ACPs and MSCs lessened the effects of DMM on mobility. Histological scoring revealed significant reductions of PTOA in the medial compartment with ACPs relative to both MSCs and vehicle controls. Overall, ACPs effectively reduced PTOA progression to a greater extent than MSCs. Conclusion: Our findings demonstrated that both equine ACP and MSC treatments provided symptom modification over vehicle controls in a short-term animal study. Notably, ACPs may be more efficacious than MSCs at reducing structural joint pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.